Page 5 - Coronavirus Vaccine

Serum Institute responds for first time on Covishield amid safety row

Serum Institute of India says it stopped manufacturing Covishield since December 2021

AstraZeneca withdraws its Covid-19 vaccine, cites 'surplus availability'

According to media reports, the Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts

FLiRT 2024: New group of Covid variants spreads in US; all you need to know

FLiRT, a group of new Covid variants in the Omicron JN.1 lineage, is spreading in the US. KP.2 and KP 1.1 are more infectious than earlier Omicron variants, which, however, have similar side effects

Plans afoot to organise Kolhapuri chappal trade but it's a slow start

Though the Kolhapuri chappal trade is robust, the industry remains largely unorganised and finds it challenging to meet demand

As Xi Jinping visits Europe, Ukraine, trade likely to be top priority

Ukraine, trade and investment are expected to dominate Chinese leader Xi Jinping's first trip to Europe in five years, as the Asian giant rebuilds its foreign relations after a prolonged absence during the Covid-19 pandemic. Xi will start the tour in Paris on Monday, meeting with French President Emmanuel Macron, who has been stressing the idea of European strategic autonomy from the U.S. On a visit to Beijing last year, Macron courted controversy by saying France would not necessarily always align with the US in foreign policy, an apparent reference to American support for the self-governing republic of Taiwan, which China claims as its own territory to be annexed by force if necessary. After leaving France, Xi will visit Hungary and Serbia, both seen as China-friendly and close to Russian President Vladimir Putin, rebuffing Western criticism of his full-scale invasion of Ukraine. Xi's European visits will be closely followed in Washington for signs of diminishing support for its k

India premier destination for global clinical trials, says Harvard scholar

India has emerged as a premier destination for conducting global clinical trials, an Indian bureaucrat who is also a Harvard scholar has said, asserting that the pharma industry must recognise the country's intrinsic value as a primary location rather than relegating it to a secondary backup role. Speaking at a recent Bio-Pharma summit in Boston, Dr Mrinalini Darswal, an Indian diplomat who is currently a PhD scholar at Harvard University, said that India "boasts a robust infrastructure, a cadre of seasoned investigators, and cost-effectiveness, collectively rendering it an appealing choice for such endeavours. The present aspirational India under the strong and transformative leadership of our Prime Minister Narendra Modi has emerged as a premier destination for conducting global clinical trials, having streamlined its regulatory framework and elevated its compliance standards to align with international good clinical practices, Darswal said. This starkly contrasts larger economies

PM Modi missing from Covid certificates after Covishield row: Here's why

Ministry of Health and Family Welfare informed that PM Modi's photo was removed from Covid certificates due to the Model Code of Conduct (MCC) in effect for the ongoing Lok Sabha polls

AstraZeneca admits Covishield has rare side effect: Is concern warranted?

AstraZeneca's acknowledgment that the vaccine may lead to thrombosis isn't a new revelation, but it underscores the need for transparent communication by the pharma companies, say experts

Covishield vaccine case: Plea filed in SC seeking probe on AstraZeneca

AstraZeneca, facing a lawsuit in UK for alleged vaccine-related deaths and injuries, has acknowledged that its vaccine can cause Thrombosis with Thrombocytopenia Syndrome (TTS)

Astrazeneca row: Only 7 in a million at risk of TTS, says ex-ICMR scientist

Former ICMR scientist Raman Gangakhedkar said the risk is highest after the initial dose, eventually decreasing with subsequent doses

Centre needs to work on war footing to deal Covishield side effects: AAP

Delhi Health Minister Saurabh Bharadwaj on Wednesday said there was need to deal with the "rare side effects" of Covishield vaccine on a war footing and alleged that the central government has done nothing so far in the matter. In a press conference, Bharadwaj said that the Centre should talk to the vaccine manufacturing company, doctors and scientists for devising a mechanism to help people detect "warning signs or symptoms" of any side effects of the vaccine. "This issue should not be politicised but the Centre has been sleeping and it has done nothing so far. This vaccine was banned in many European countries in 2021 when government in our country was administering and promoting it, " he said. Bharadwaj said there were already questions in the minds of the people if the vaccine was in any way linked to the "sudden rise in heart attack cases". There were numerous videos of people suddenly collapsing and dying during workouts and other such normal activities in different parts of

Parents to sue Serum Institute over daughter's alleged Covishield death

Father says that AstraZeneca's admission of vaccine's rare side effect is 'too late'

AstraZeneca responds to Covishield vaccine concerns: Here's what they said

Regulatory agencies around the world maintain that the risks from the vaccine outweigh the benefits

Chinese scientist who published Covid-19 virus sequence back in his lab

The first scientist to publish a sequence of the COVID-19 virus in China said he was allowed back into his lab after he spent days locked outside, sitting in protest. Zhang Yongzhen wrote in an online post early on Wednesday that authorities had tentatively agreed to allow him and his team to return to his laboratory and continue their research for the time being. Zhang had been staging a sit-in protest outside his lab since the weekend after he and his team were suddenly notified they had to leave their lab, a sign of Beijing's continuing pressure on scientists conducting research on the coronavirus. The Shanghai Public Health Clinical Center previously said Zhang's lab was being renovated and was closed for safety reasons. But Zhang said his team wasn't offered an alternative until after the eviction and the new lab didn't meet safety standards for conducting their research. Zhang's latest difficulty reflects how China has sought to control information related to the virus: An ..

AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns

This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria "can, in very rare cases, cause TTS

AstraZeneca vaccine: From its origin to side effects, all you need to know

Manufactured first in 2021, the AstraZeneca vaccine, known in India as Covishield, has been facing scrutiny over the years, with many countries banning it back in 2021 itself

AstraZeneca's Covishield causes rare blood clot disorder TTS: What is it?

Covishield, a vaccine developed by AstraZeneca and Oxford University and manufactured by the Serum Institute of India, can, in rare instances, lead to TTS

AstraZeneca admits its Covishield vaccine may lead to rare side effect

AstraZeneca has admitted for the first time in court documents that its Covid vaccine can cause rare side effects, marking an about-turn that may open the door for a multi-million pound legal payout

China's top Covid-19 vaccine scientist expelled from Parliament for graft

China's top scientist, who developed the first inactivated COVID-19 vaccine at the height of the pandemic in the country in 2020, has been dismissed from Parliament for alleged corruption. Yang Xiaoming, the chairman of China National Pharmaceutical Group's vaccine subsidiary China National Biotec Group (CNBG), has been stripped of his membership in the National People's Congress (NPC) due to serious discipline and law violations, official media reported here on Monday. The charge of serious discipline and law violations is a common euphemism for corruption under the ruling Communist Party of China (CPC) disciplinary practice. Yang, 62, is a veteran researcher who headed the CNBG - a vaccine subsidiary of state-owned Sinopharm - and led a team that developed Sinopharm's BBIBP-CorV vaccine, China's first coronavirus shot approved for general use. Coronavirus first surfaced in the Chinese city of Wuhan in March 2020 and later spread to the world, becoming the pandemic of the century

GlaxoSmithKline sues Pfizer, BioNTech over Covid-19 vaccine technology

GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of COVID-19